Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy

Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy

Abstract Immune checkpoint inhibitors (ICIs) are a key component of first-line treatment for metastatic renal cell carcinoma (mRCC). However, predicting treatment-related adverse events (TRAEs) remains challenging. This study investigated the utility of eosinophil-related biomarkers as predictors of...

Full description

Saved in:
Bibliographic Details
Main Authors: Tatsushi Kawada, Satoshi Katayama, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Kazumasa Komura, Takuya Tsujino, Ryoichi Maenosono, Kiyoshi Takahara, Takuhisa Nukaya, Lan Inoki, Shingo Toyoda, Takeshi Hashimoto, Yosuke Hirasawa, Kohei Edamura, Tomoko Kobayashi, Kensuke Bekku, Shingo Nishimura, Takehiro Iwata, Takuya Sadahira, Yusuke Tominaga, Tomoaki Yamanoi, Kasumi Yoshinaga, Kazuma Tsuboi, Yasuyuki Kobayashi, Atsushi Takamoto, Kyohei Kurose, Takahiro Kimura, Haruhito Azuma, Ryoichi Shiroki, Kazutoshi Fujita, Yoshio Ohno, Motoo Araki, On behalf of JK-FOOT study group
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Renal cell carcinoma
Immune checkpoint inhibitor
ICI
Eosinophil
Immune-related adverse event
Treatment-related adverse event
Online Access:https://doi.org/10.1038/s41598-025-08767-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-08767-9

Similar Items